BIOMAT Database Logo BIOMAT Database Logo

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. 2018

Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
From the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada. lmidaglia@cem-cat.org.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074323 Alemtuzumab An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY. Campath,Campath 1G,Campath 1H,Campath 1M,Campath-1-G,Campath-1G,Campath-1H,Campath-1M,Lemtrada,MabCambath,Monoclonal Antibody Campath-1H,Antibody Campath-1H, Monoclonal,Campath 1 G,Campath-1H, Monoclonal Antibody,Campath1G,Campath1H,Monoclonal Antibody Campath 1H
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
March 2012, Expert review of neurotherapeutics,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Alemtuzumab therapy for multiple sclerosis.
January 2013, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Multiple sclerosis and myasthenia gravis following severe weight loss.
April 2018, Neurosciences (Riyadh, Saudi Arabia),
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Myasthenia gravis and multiple sclerosis.
June 1983, Journal of neuroimmunology,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Goodpasture's Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis.
November 2018, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
[Multiple sclerosis associated with myasthenia gravis].
January 1990, Sovetskaia meditsina,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
November 2018, Multiple sclerosis (Houndmills, Basingstoke, England),
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
May 2017, Multiple sclerosis and related disorders,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
[Coexistence of multiple sclerosis and myasthenia gravis].
January 1991, Neurologia i neurochirurgia polska,
Luciana Midaglia, and Margarida Gratacòs, and Edoardo Caronna, and Nuria Raguer, and Jaume Sastre-Garriga, and Xavier Montalban, and Mar Tintoré
Melanoma following treatment with alemtuzumab for multiple sclerosis.
April 2009, European journal of neurology,
Copied contents to your clipboard!